Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of ARDX is 13 and suggests 63% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell